V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10002805 | 10001824 | 1.61 | 53.9 | Palliative (P) | 2017-12-11 | 2017-12-28 | PEMBROLIZUMAB | 02 | N | 10448154 | PEMBROLIZUMAB |
| 10002806 | 10001825 | 0 | 68 | Curative (C) | null | 2013-08-07 | CVP R | 02 | N | 10448243 | CVP R |
| 10002807 | 10001826 | 1.78 | 65 | Palliative (P) | 2016-11-09 | 2016-11-09 | Gemcitabine 1000mg/m2 D1 8 15 | 2 | N | 10448248 | GEMCITABINE |
| 10002808 | 10001827 | 1.5 | 62.6 | Palliative (P) | 2016-09-15 | 2016-09-29 | CARBOPLATIN + VINORELBINE | N | N | 10448316 | CARBOPLATIN + VINORELBINE |
| 10002809 | 10001828 | 1.48 | 75.3 | Palliative (P) | 2018-01-04 | 2018-01-15 | PEMBROLIZUMAB | 02 | N | 10448323 | PEMBROLIZUMAB |
| 10002810 | 10001829 | 1.72 | 80.2 | Neo-adjuvant (N) | 2015-10-01 | 2015-10-17 | ECX | N | N | 10448331 | ECX |
| 10002811 | 10001830 | null | 0 | Disease modification (D) | 2015-07-25 | 2015-08-05 | Hydroxycarbamide | 2 | N | 10448433 | HYDROXYCARBAMIDE |
| 10002812 | 10001830 | 0 | 62.2 | Curative (C) | 2018-01-26 | 2018-02-02 | CVP R | 02 | N | 10448433 | CVP R |
| 10002813 | 10001831 | 1.65 | 0 | Palliative (P) | 2017-08-23 | 2017-09-07 | Carboplatin + Vinorelbine IV | 2 | N | 10448518 | CARBOPLATIN + VINORELBINE |
| 10002814 | 10001832 | 1.51 | 88.6 | Palliative (P) | 2018-05-03 | 2018-05-10 | Trial Unspecified | N | null | 10448599 | TRIAL |
| 10002815 | 10001832 | null | 88 | Neo-adjuvant (N) | 2017-12-28 | 2018-01-07 | EOX | N | Y | 10448599 | EOX |
| 10002816 | 10001832 | 0 | 59.6 | Neo-adjuvant (N) | 2017-12-23 | 2017-12-30 | ECX | N | N | 10448599 | ECX |
| 10002817 | 10001832 | 1.84 | 48.8 | Palliative (P) | 2017-05-14 | 2017-06-17 | Enzalutamide | 02 | N | 10448599 | ENZALUTAMIDE |
| 10002818 | 10001833 | 1.8 | 79 | Palliative (P) | 2016-07-20 | 2016-07-29 | PEMBROLIZUMAB | 2 | N | 10448883 | PEMBROLIZUMAB |
| 10002819 | 10001834 | null | 97.2 | Disease modification (D) | 2017-03-26 | 2017-03-30 | Rituximab | N | N | 10448905 | RITUXIMAB |
| 10002820 | 10001835 | null | 48 | Palliative (P) | 2018-08-23 | 2018-08-30 | EOX | N | N | 10448984 | EOX |
| 10002821 | 10001835 | 0 | 91.85 | Disease modification (D) | 2017-08-06 | 2017-08-06 | Rituximab | 02 | N | 10448984 | RITUXIMAB |
| 10002822 | 10001835 | null | null | Disease modification (D) | 2018-02-08 | 2018-02-08 | Hydroxycarbamide | 2 | N | 10448984 | HYDROXYCARBAMIDE |
| 10002823 | 10001835 | 1.72 | 100.8 | Palliative (P) | 2015-06-10 | 2015-06-22 | PEMBROLIZUMAB | 2 | N | 10448984 | PEMBROLIZUMAB |
| 10002824 | 10001836 | 1.8 | 93.4 | Palliative (P) | 2017-06-21 | 2017-06-20 | Hydroxycarbamide | 02 | N | 10449101 | HYDROXYCARBAMIDE |
| 10002825 | 10001836 | 1.7 | 80.6 | Disease modification (D) | 2016-07-25 | 2016-08-14 | Rituximab | 02 | N | 10449101 | RITUXIMAB |
| 10002826 | 10001836 | 0 | 69 | Palliative (P) | 2017-12-10 | 2017-12-18 | Hydroxycarbamide | N | N | 10449101 | HYDROXYCARBAMIDE |
| 10002827 | 10001837 | null | null | Palliative (P) | 2013-11-10 | 2013-11-11 | EOX | N | null | 10449421 | EOX |
| 10002828 | 10006286 | 1.69 | 86.4 | Curative (C) | 2017-05-15 | 2017-05-25 | Rituximab | N | N | 10449474 | RITUXIMAB |
| 10002829 | 10006286 | 1.62 | 87.2 | Curative (C) | 2018-12-04 | 2018-12-11 | PEMBROLIZUMAB | 2 | N | 10449474 | PEMBROLIZUMAB |
| 10002830 | 10001838 | null | 65 | Neo-adjuvant (N) | 2015-11-04 | 2015-11-13 | ECX | N | N | 10449517 | ECX |
| 10002831 | 10001839 | 1.6 | 49 | Curative (C) | 2016-11-10 | 2016-11-10 | CVP R | N | N | 10449576 | CVP R |
| 10002832 | 10006287 | 1.56 | 62.1 | Adjuvant (A) | 2017-09-29 | 2017-10-28 | Trial Unspecified | Y | N | 10449592 | TRIAL |
| 10002833 | 10001840 | null | null | Curative (C) | 2016-08-05 | 2016-08-15 | Hydroxycarbamide | N | N | 10449617 | HYDROXYCARBAMIDE |
| 10002834 | 10001841 | 1.74 | 102.2 | null | 2016-10-12 | 2016-10-13 | CARBOPLATIN + VINORELBINE | 2 | N | 10449625 | CARBOPLATIN + VINORELBINE |
| 10002835 | 10001842 | null | 87.65 | Palliative (P) | 2014-08-29 | 2014-08-29 | Carboplatin + Vinorelbine IV | N | N | 10449640 | CARBOPLATIN + VINORELBINE |
| 10002836 | 10001843 | 1.73 | 95.8 | Palliative (P) | 2016-06-08 | 2016-06-14 | EOX | N | N | 10449649 | EOX |
| 10002837 | 10001844 | 1.65 | null | Curative (C) | 2016-10-30 | 2016-12-05 | Cisplatin + Vinorelbine (PO) | N | N | 10449668 | CISPLATIN + VINORELBINE |
| 10002838 | 10001845 | 1.6 | 70.9 | Palliative (P) | 2016-03-26 | 2016-04-02 | EOX | 02 | N | 10449675 | EOX |
| 10002839 | 10001845 | 0 | 0 | Disease modification (D) | 2017-01-15 | 2017-01-15 | CVP R | N | N | 10449675 | CVP R |
| 10002840 | 10001846 | 1.61 | 67.8 | Palliative (P) | 2017-10-25 | 2017-10-25 | Cisplatin + Vinorelbine (PO) | 02 | N | 10449767 | CISPLATIN + VINORELBINE |
| 10002841 | 10001847 | 1.72 | 86.35 | Palliative (P) | 2019-05-10 | 2019-05-17 | Enzalutamide | 2 | N | 10449815 | ENZALUTAMIDE |
| 10002842 | 10001847 | 1.63 | 59 | Palliative (P) | 2017-12-20 | 2017-12-25 | PEMBROLIZUMAB | N | N | 10449815 | PEMBROLIZUMAB |
| 10002843 | 10001847 | 1.51 | 61 | Adjuvant (A) | 2016-04-12 | 2016-04-18 | Gemcitabine weekly | 02 | N | 10449815 | GEMCITABINE |
| 10002844 | 10001848 | 1.61 | 57.38 | Curative (C) | 2016-10-30 | 2016-11-01 | Hydroxycarbamide | 02 | N | 10449925 | HYDROXYCARBAMIDE |
| 10002845 | 10006290 | 1.82 | 69 | Neo-adjuvant (N) | 2018-01-21 | 2018-02-19 | ECX | N | N | 10450022 | ECX |
| 10002846 | 10006290 | 1.55 | 42.9 | null | 2018-04-03 | 2018-04-09 | Trial Unspecified | Y | N | 10450022 | TRIAL |
| 10002847 | 10008771 | 1.74 | 81.9 | Adjuvant (A) | 2017-07-24 | 2017-07-25 | Cisplatin + Vinorelbine (PO) | 02 | N | 10450045 | CISPLATIN + VINORELBINE |
| 10002848 | 10008771 | 1.87 | null | Palliative (P) | 2014-10-16 | 2014-10-20 | ECX | N | N | 10450045 | ECX |
| 10002849 | 10001849 | null | 48.65 | Adjuvant (A) | 2015-07-08 | 2015-07-09 | Cisplatin + Vinorelbine (PO) | N | N | 10450124 | CISPLATIN + VINORELBINE |
| 10002850 | 10001849 | null | 83 | Adjuvant (A) | 2016-01-13 | 2016-01-26 | ECX | 02 | N | 10450124 | ECX |
| 10002851 | 10001849 | 1.62 | 77.8 | Adjuvant (A) | 2018-10-28 | 2018-11-20 | ECX | N | N | 10450124 | ECX |
| 10002852 | 10001849 | 1.75 | null | Palliative (P) | 2014-05-15 | 2014-05-23 | Gemcitabine 1000mg/m2 D1 8 15 | N | N | 10450124 | GEMCITABINE |
| 10002853 | 10001849 | 1.79 | 85.2 | Neo-adjuvant (N) | 2012-11-24 | 2013-05-06 | Trial Unspecified | Y | N | 10450124 | TRIAL |
| 10002854 | 10001850 | 1.61 | 0 | Palliative (P) | 2019-01-18 | 2018-01-17 | Cisplatin + Pemetrexed | 02 | N | 10450259 | CISPLATIN + PEMETREXED |